---
title: "Analyst Maintains Buy on Tovecimig Developer, Sees PFS Strength Underappreciated and Keeps $24 Price Target Unchanged"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284246322.md"
description: "H.C. Wainwright analyst Joseph Pantginis has reiterated a Buy rating on CMPX stock, maintaining a $24 price target. He cites the strength of tovecimig’s progression-free survival data in biliary tract cancer as a key factor, suggesting the market undervalues its clinical benefits. Pantginis views recent share weakness as due to regulatory uncertainty rather than drug failure, and anticipates a successful FDA dialogue and potential U.S. approval in 2027."
datetime: "2026-04-27T15:55:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284246322.md)
  - [en](https://longbridge.com/en/news/284246322.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284246322.md)
---

# Analyst Maintains Buy on Tovecimig Developer, Sees PFS Strength Underappreciated and Keeps $24 Price Target Unchanged

H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on CMPX stock, giving a Buy rating today.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Joseph Pantginis has given his Buy rating due to a combination of factors, primarily the strength of tovecimig’s progression-free survival data in second-line biliary tract cancer. He highlights that the regimen meaningfully lengthens the time patients live without disease worsening versus standard chemotherapy and even exceeds a key historical benchmark, indicating clinically relevant benefit that he believes the market is undervaluing.

At the same time, Pantginis views the overall-survival readout as confounded rather than negative, given the high crossover rate from the control arm to tovecimig, and points to exploratory analyses and PFS2 data as supportive of true drug activity. He therefore interprets the recent share weakness as driven by regulatory uncertainty, not by a failure of the drug, and maintains an unchanged $24 price target based on the potential for a successful FDA dialogue, a planned BLA submission around year-end 2026, and a possible U.S. approval in 2027.

### Related Stocks

- [CMPX.US](https://longbridge.com/en/quote/CMPX.US.md)

## Related News & Research

- [Compass Therapeutics: Buy Rating Reiterated as Clinical Progress Strengthens Approval Odds; $6 Price Target Maintained](https://longbridge.com/en/news/285256239.md)
- [This Analyst Just Sent Mobileye Stock Down. Here's Why.](https://longbridge.com/en/news/286817003.md)
- [Do Wall Street Analysts Like Equity Residential Stock?](https://longbridge.com/en/news/286806057.md)
- [Core Scientific Is Firing on All Cylinders as Analysts Approve Its Expansion Plans](https://longbridge.com/en/news/286808678.md)
- [Walmart Stock: Here’s Why Analysts Are Raising Price Targets Before Q1 Earnings.](https://longbridge.com/en/news/286950969.md)